Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference.
Mr. Tornos said adoption of the robot remains strong, and the company plans to launch three Rosa indications in the next 18 months, according to a March 13 investing.com transcript.
Rosa, which has been Zimmer Biomet’s flagship total knee replacement robot, earned FDA approval for its shoulder application in 2024.
